J. Biol. Chem., Vol. 266, Issue 7, 4041-4044, 03, 1991

On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator

HR Lijnen, B Van Hoef and D Collen
Center for Thrombosis and Vascular Research, K.U. Leuven, Belgium.

The reaction between plasminogen activators and plasminogen activator inhibitor-1 is characterized by an initial rapid formation of an inactive reversible complex. The second-order association rate constant (k1) of complex formation of recombinant two-chain tissue-type plasminogen activator (rt-PA) or recombinant two-chain urokinase-type plasminogen activator (rtcu-PA) by recombinant plasminogen activator inhibitor-1 (rPAI-1) is 2.9 +/- 0.4 x 10(7) M-1 s-1 (mean +/- S.D., n = 30) and 2.0 +/- 0.6 x 10(7) M-1 s-1 (n = 12), respectively. Different molecular forms of tissue- or urokinase-type plasminogen activator which do not form covalent complexes with rPAI-1, including rt-PA- Ala478 (rt-PA with the active-site Ser478 mutagenized to Ala) and anhydro-urokinase (rtcu-PA with the active-site Ser356 converted to dehydroalanine) reduced k1 in a concentration-dependent manner, compatible with 1:1 stoichiometric complex formation between rPAI-1 and these ligands. The apparent dissociation constant (KD) of the complex between rPAI-1 and rt-PA-Ala478, determined as the concentration of rt- PA-Ala478 which reduced k1 to 50% of its control value, was 3-5 nM. Corresponding concentrations of active-site-blocked two-chain rt-PA were 150-250-fold higher. The concentration of anhydro-urokinase which reduced k1 to 50% was 4-6 nM, whereas that of active-site-blocked rtcu- PA was 100-250-fold higher. Recombinant single-chain urokinase-type plasminogen activator had an apparent KD of about 2 microM. These results suggest that inhibition of rt-PA or rtcu-PA by rPAI-1 proceeds via a reversible high affinity interaction which does not require a functional active site but which is markedly reduced following inactivation of the enzymes with active-site titrants.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Longstaff, R. E. Merton, P. Fabregas, and J. Felez Characterization of Cell-Associated Plasminogen Activation Catalyzed by Urokinase-Type Plasminogen Activator, but Independent of Urokinase Receptor (uPAR, CD87) Blood, June 1, 1999; 93(11): 3839 - 3846. [Abstract] [Full Text] [PDF]

				N. M. Schechter, M. Plotnick, T. Selwood, M. Walter, and H. Rubin Diverse Effects of pH on the Inhibition of Human Chymase by Serpins J. Biol. Chem., September 26, 1997; 272(39): 24499 - 24507. [Abstract] [Full Text] [PDF]

				S. T. Olson, R. Swanson, P. A. Patston, and I. Bjork Apparent Formation of Sodium Dodecyl Sulfate-stable Complexes between Serpins and 3,4-Dichloroisocoumarin-inactivated Proteinases Is Due to Regeneration of Active Proteinase from the Inactivated Enzyme J. Biol. Chem., May 16, 1997; 272(20): 13338 - 13342. [Abstract] [Full Text] [PDF]

				S. Anand and S. L. Diamond Computer Simulation of Systemic Circulation and Clot Lysis Dynamics During Thrombolytic Therapy That Accounts for Inner Clot Transport and Reaction Circulation, August 15, 1996; 94(4): 763 - 774. [Abstract] [Full Text]

				S. T. Olson, P. E. Bock, J. Kvassman, J. D. Shore, D. A. Lawrence, D. Ginsburg, and I. Björk Role of the Catalytic Serine in the Interactions of Serine Proteinases with Protein Inhibitors of the Serpin Family J. Biol. Chem., December 15, 1995; 270(50): 30007 - 30017. [Abstract] [Full Text] [PDF]